Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma

Clinical Biochemistry

Volumn 36, Issue 7, 2003, Pages 537-543

  Reda Mabrouk, Randa Abdel Wahab ^a   Ali Labib, Randa ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

c erbB 2; CA125; CA15.3; uPAR

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; ONCOPROTEIN; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OVARY CARCINOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0141918832     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(03)00102-4     Document Type: Article

References (42)

1. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 82:1999;298-304.
2. Colomer R., Montero S., Lluch A., Ojeda B., Barnadas A., Casado A., Massuti B., Cortes-Funes H., Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 6:2000;2356-2362.
3. Slot O., Brunner N., Locht H., Oxholm P., Stephens R.W. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders increased concentrations in rheumatoid arthritis . Ann Rheum Dis. 58:1999;488-492.
4. Hjertner O., Qvigstad G., Hjorth-Hansen H., Seidel C., Woodliff J., Epstein J., Waage A., Sundan A., Borset M. Expression of urokiase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol. 109:2000;815-822.
5. Sier C.F., Stephens R., Bizik J., Mariani A., Bassan M., Pederson N., Frigerio I., Ferrari A., Dano K., Brunner N., Blassi F. The level of urokinase-type plasminogen receptor is increased in serum of ovarian cancer patients. Cancer Res. 58:1998;1843-1849.
6. Gong S.J., Rha S.Y., Chung H.C., Yoo N.C., Rho J.K., Yang W.I., Lee K.S., Min J.S., Kim B.S. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Int J Mol Med. 6:2000;301-305.
7. Aunoble B., Sanches R., Didier E., Bignon Y.J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol. 16:2000;567-576.
8. Reese D.M., Slamon D.J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 15:1997;1-8.
9. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
10. Slamon D.J., Clark J.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
11. Meden H., Marx D., Roegglen T., Schauer A., Kuhn W. Overexpression of the oncogene c-erbB-2 (HER-2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol. 17:1998;61-65.
12. Hengstler J.G., Lange J., Kett A., Dornhofer N., Arand M., Knapstein P.G., Becker R., Oesch F., Tanner B. Contribution of c-erbB-2 and Topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res. 59:1999;3206-3214.
13. Abendstein B., Daxenbichler G., Windbichler G., Zeimet A.G., Geurts A., Sweep F., Marth C. Predictive value of uPA, PAI-1, Her-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res. 20:2000;569-572.
14. Streckfus C.F., Bigler L., Dellinger T., Dai X., Kingman A., Thigpen J.T. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma A preliminary study . Clin Cancer Res. 6:2000;2363-2370.
15. nd ed. Cold Spring Harbor, Laboratory Press. 18:1989;42-57.
16. Eissa S., Seada L.S. Quantitation of bcl-2 in bladder cancer tissue Comparison with Westernblot and Immuno-histochemistry . Clin Chem. 77:1998;1427-1432.
17. Fisher J.L., Field C.L., Zhou H., Harris T.L., Henderson M.A., Choong P.F. Urokinase plasminogen activator system gene expession is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non invasive carcinoma and osseous metastases. Breast Cancer Res Treat. 61:2000;1-12.
18. Behrendt N., Stephens R.W. The urokinase receptor. Fibrinolysis and proteolysis. 12:1998;191-204.
19. Goa W., Wang Z., Bai X., Xi X., Ruan C. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res. 102:2001;25-31.
20. Rha S.Y., Yang W.I., Gong S.J., Kim J.J., Yoo N.C., Roh J.K., Min J.S., Lee K.S., Kim B.S., Chung H.C. Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Lett. 150:2000;137-145.
21. Riisbro R., Stephens R.W., Brunner N., Christensen I.J., Nielsen H.J., Heilmann L., von-Tempelhoff G.F. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol. 82:2001;523-531.
22. Ouyang X., Gulliford T., Doherty A., Huang G., Epstein R. Detection of ErbB-2 oversignalling in a majority of breast cancers with phosphorylation-state specific antibodies. Lancet. 353:1999;1591-1592.
23. Felip E., Del Campo J.M., Rubio D., Vidal M.T., Colomer R., Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer. 75:1995;2147-2152.
24. Koscielny S., Terrier P., Spielmann M., Delarue J.C. Prognostic importance of low c-erbB-2 expression in breast tumors. J Natl Cancer Inst. 90:1998;71.
25. Volas G.H., Leitzel K., Teramoto Y., Grossber H., Demeres L., Lipton A. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer. 78:1996;267-272.
26. Fajac A., Benard J., Lhomme C., Rey A., Duvillard P., Rochard F., Bernaudin J.F., Riou G. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors evaluation of their respective prognostic significance by multivariate analysis . Int J Cancer. 64:1995;146-151.
27. Meden H., Marx D., Fattahi A., Rath W., kron M., Wuttke W., Schauer A., Kuhn W. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol. 120:1994;378-381.
28. Breuer B., Smith S., Thor A., Edgerton S., Osborne M., Minick C.R., Cody H., Nowak E.J., Cortese A., Simmons R., Carney W.P., Brandt-Rauf P.W. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat. 49:1998;261-270.
29. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer prognostic factor, predictive factor, and target for therapy . Oncologist. 3:1998;237-252.
30. Stenman U.H., Heikkinen R. Serum markers for breast cancer. Scand J Clin Lab Investig. 206:1991;52-59.
31. Gooderham, K. Protein blotting. In: techniques in molecular biology. Edited by: Walker, J.M. and Gaastra, W. Croom Helim Publishers. 1983:49.
32. Zabrecky J.R., Lam T., McKenzie S.J., Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem. 266:1991;1716-1720.
33. Narita T., Funahashi H., Satoh Y., Takagi H. c-erbB-2 protein in sera of breast cancer patients. Breast Cancer Res Treat. 24:1992;97-102.
34. Leitzel K., Teramoto Y., Sampson E., Mauceri J., Langton B.C., Demers I., Podezaski E., Harvey H., Shambaugh S., Volas G., Weaver S., Lipton A. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol. 10:1992;1436-1443.
35. Breuer B., DeVivo I., Luo J.C., Smith S., Pincus M.R., Tatum A.H., Daucher J., Minick C.R., Miller D., Nowak E.J., Cody H.S.I.I.I., Nimar H., Carney W.P., Brandt-Rauf P.W. c-erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomark Prev. 3:1994;63-66.
36. Watanabe N., Miyamoto M., Tokuda Y., Kubota M., Ando Y., Tajima T., Mitomi T. Serum c-erbB-2 in breast cancer patients. Acta Oncol. 33:1994;901-904.
37. Imoto S., Kitoh T., Hasebe T. Serum c-erbB-2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol. 29:1999;336-339.
38. Yazici H., Dolapcioglu K., Buyru F., Dalay N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Invest. 18:2000;110-114.
39. Marx D., Fattahi-Meibodi A., Kudellka R., Uebel T., Kuhn W., Meden H. Detection of p105 (c-erbB-2, Her2/neu) serum levels by a new ELISA in patients with ovarian carcinoma. Anticancer Res. 18:1998;2891-2894.
40. Rubin S.C., Finstad C.L., Wong G.Y., Almadrones L., Plante M., Lloyd K.O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer a multivariate analysis . Am J Obstet Gynecol. 168:1993;162-169.
41. van-der-Zee A.G., Hollema H., Suurmeijer A.J., Krans M., Sluiter W.J., Willemse P.H., Aalders J.G., de-Vries E.G. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 13:1995;70-78.
42. Agus D.B., Bunn P.A., Franklin W., Garcia M., Ozols R.F. Her-2/neu as a therapeutic target in non-small lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 27:2000;53-63.